135 related articles for article (PubMed ID: 1954636)
21. Idarubicin in the therapy of acute myeloid leukemia: final analysis in 57 previously untreated patients.
Lambertenghi Deliliers G; Annaloro C; Oriani A; Pozzoli E; Cortelezzi A; Cortellaro M; Mozzana R; Della Volpe A; Soligo D; Cofrancesco E
Semin Oncol; 1993 Dec; 20(6 Suppl 8):27-33. PubMed ID: 8290969
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
Lemez P; Maresová J
Semin Oncol; 1998 Aug; 25(4 Suppl 10):61-5. PubMed ID: 9768826
[TBL] [Abstract][Full Text] [Related]
23. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Vogler WR; Velez-Garcia E; Omura G; Raney M
Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
[No Abstract] [Full Text] [Related]
24. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
25. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
[TBL] [Abstract][Full Text] [Related]
26. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T
Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320
[TBL] [Abstract][Full Text] [Related]
27. Idarubicin combined with intermediate-dose cytosine arabinoside in the treatment of refractory acute leukemia.
Leone G; Pagano L; Marra R; Di Pietro N; Storti S; Sica S; D'Onofrio G; Ganzina F
Haematologica; 1989; 74(1):57-61. PubMed ID: 2498185
[TBL] [Abstract][Full Text] [Related]
28. Comparison of survival. Chemotherapeutically treated and untreated older patient with acute myeloid leukemia.
Siddiqui T; Durkin WJ; Conley NS; Doughney KB; Favis GR; Weiss R; Smith AE
J Fla Med Assoc; 1994 Jul; 81(7):475-7. PubMed ID: 7964574
[TBL] [Abstract][Full Text] [Related]
29. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
[TBL] [Abstract][Full Text] [Related]
30. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Miyawaki S; Tanimoto M; Kobayashi T; Minami S; Tamura J; Omoto E; Kuriyama K; Hatake K; Saito K; Kanamaru A; Oh H; Ohtake S; Asou N; Sakamaki H; Yamada O; Jinnai I; Tsubaki K; Takeyama K; Hiraoka A; Matsuda S; Takahashi M; Shimazaki C; Adachi K; Kageyama S; Ohno R
Int J Hematol; 1999 Aug; 70(2):97-104. PubMed ID: 10497848
[TBL] [Abstract][Full Text] [Related]
31. [Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin].
Lemez P; Gáliková J; Haas T
Vnitr Lek; 1999 Jun; 45(6):342-6. PubMed ID: 11045169
[TBL] [Abstract][Full Text] [Related]
32. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
[TBL] [Abstract][Full Text] [Related]
33. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
[TBL] [Abstract][Full Text] [Related]
34. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
Vogler WR; Velez-Garcia E; Weiner RS; Flaum MA; Bartolucci AA; Omura GA; Gerber MC; Banks PL
J Clin Oncol; 1992 Jul; 10(7):1103-11. PubMed ID: 1607916
[TBL] [Abstract][Full Text] [Related]
35. New agents in the treatment of acute myeloid leukemia.
Wiernik PH
Semin Hematol; 1991 Jul; 28(3 Suppl 4):95-8. PubMed ID: 1780763
[No Abstract] [Full Text] [Related]
36. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.
Mandelli F; Petti MC; Ardia A; Di Pietro N; Di Raimondo F; Ganzina F; Falconi E; Geraci E; Ladogana S; Latagliata R
Eur J Cancer; 1991; 27(6):750-5. PubMed ID: 1829918
[TBL] [Abstract][Full Text] [Related]
37. Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug.
Marie JP; Wdowik T; Bisserbe S; Zittoun R
Leukemia; 1992 Jul; 6(7):720-2. PubMed ID: 1625492
[TBL] [Abstract][Full Text] [Related]
38. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Berman E; Heller G; Santorsa J; McKenzie S; Gee T; Kempin S; Gulati S; Andreeff M; Kolitz J; Gabrilove J
Blood; 1991 Apr; 77(8):1666-74. PubMed ID: 2015395
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy.
Broxterman HJ; Sonneveld P; van Putten WJ; Lankelma J; Eekman CA; Ossenkoppele GJ; Pinedo HM; Löwenberg B; Schuurhuis GJ
Leukemia; 2000 Jun; 14(6):1018-24. PubMed ID: 10865967
[TBL] [Abstract][Full Text] [Related]
40. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Giles FJ; Kantarjian HM; Cortes JE; Garcia-Manero G; Verstovsek S; Faderl S; Thomas DA; Ferrajoli A; O'Brien S; Wathen JK; Xiao LC; Berry DA; Estey EH
J Clin Oncol; 2003 May; 21(9):1722-7. PubMed ID: 12721247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]